Research programme: protein-protein interaction blockers - Vipergen
Latest Information Update: 28 Sep 2018
At a glance
- Originator Vipergen ApS
- Class Small molecules
- Mechanism of Action Interleukin 17 receptor antagonists; Interleukin 6 receptor antagonists; Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Inflammation
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for research development in Cancer in Denmark
- 28 Aug 2018 No recent reports of development identified for research development in Autoimmune-disorders in Denmark
- 28 Aug 2018 No recent reports of development identified for research development in Inflammation in Denmark